Video

Practical Considerations for Selection of PSMA-PET Tracers

Author(s):

Phillip Koo, MD,Michael S. Cookson, MD, MMHC

Experts discuss practical considerations on selection among available PSMA-PET tracer options for prostate cancer imaging, including regional availability, scheduling, and preparation requirements.

Related Videos
1 expert in this video
1 expert in this video
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
1 expert in this video
Man talking with doctor | Image Credit: © Khunatorn - stock.adobe.com
Related Content
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
May 20th 2025

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Hannah Clarke
The phase 3 study design will now be submitted for final review by the agency.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
SBRT may offer a safe alternative to CFRT after prostatectomy
May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Conceptual image for prostate cancer treatment, 3D illustration showing destruction of a tumor inside prostate gland | Image Credit: © Dr_Microbe - stock.adobe.come
May 13th 2025

MRI and focal therapy may enable men on AS to safely delay surgery or radiation

Hannah Clarke
Use of focal therapy was shown to prolong the duration of active surveillance.
Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC
May 6th 2025

Phase 2 trial launches of (177Lu) rhPSMA-10.1 injection in mCRPC

Hannah Clarke
Initial study results may be available as soon as the first half of 2026.
© 2025 MJH Life Sciences

All rights reserved.